ARTICLE
27 February 2024

PMPRB "What We Learned Report" Released

C
Cassels

Contributor

Cassels Brock & Blackwell LLP is a leading Canadian law firm focused on serving the advocacy, transaction and advisory needs of the country’s most dynamic business sectors. Learn more at casselsbrock.com.
The Patented Medicine Prices Review Board Canada (PMPRB) published its "What We Learned Report" (Report) on February 15, 2024...
Canada Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

The Patented Medicine Prices Review Board Canada (PMPRB) published its " What We Learned Report" (Report) on February 15, 2024, which summarizes Policy Roundtable Discussions (Policy Roundtable) held in December 2023. A separate report will be released on the analysis of the written submissions.

The Policy Roundtable invited participants to join in-person and virtually and 34 stakeholder presentations were accepted to participate. Stakeholder groups included: rights holders, industry, and industry associations; patients and patient advocacy groups; distributors, pharmacies, and pharmacy associations; civil society groups and unions; academics; a health practitioner; an individual; and a research funding organization.

Stakeholders focused on topics and issues such as:

  • The PMPRB mandate;
  • Assessing excessive pricing;
  • Considerations for PMPRB Guidelines;
  • Understanding the life sciences ecosystem;
  • Alignment of PMPRB Guidelines with broader government initiatives; and
  • Stakeholder engagement.

For further details, please see the report here.

BACKGROUND

As we reported, the Patented Medicine Prices Review Board (PMPRB) adopted its Amended Interim Guidance (Interim Guidance) on September 27, 2023. The Interim Guidance provides information on how the PMPRB reviews the prices of patented medicines in Canada and will be in force until the New Guidelines are developed and implemented.

The Policy Roundtable, as we reported, was to focus on:

  • Efficient Monitoring of Prices without Price Setting;
  • Transition to PMPRB11 – New versus Existing Medicines;
  • Price Reviews during Product Life Cycle;
  • Investigations and Referral to Hearing;
  • Relation to pan-Canadian Health Partners, Insurers (Private and Public) and Alignment with Broader Government Initiatives; and
  • Engaging with Patients, Health Practitioners, Pharmacy, and other Stakeholders.

As previously reported, the PMPRB also published a Scoping Paper for the Consultation on the Board's Guidelines (Scoping Paper) outlining further details on the consultation process and aimed to facilitate the consultation process in an informed, focused and productive manner.

NEXT STEPS

The PMPRB is continuing to review feedback it has received and will be announcing next steps soon. The Report was released after the first phase of consultations.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

ARTICLE
27 February 2024

PMPRB "What We Learned Report" Released

Canada Food, Drugs, Healthcare, Life Sciences

Contributor

Cassels Brock & Blackwell LLP is a leading Canadian law firm focused on serving the advocacy, transaction and advisory needs of the country’s most dynamic business sectors. Learn more at casselsbrock.com.
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More